

Adipose tissue, metabolic and inflammatory responses to stroke are altered in obese mice.

Haley, Michael ; Mullard, Graham; Hollywood, Katherine; Cooper, Garth J; Dunn, Warwick; Lawrence, Catherine

DOI:
[10.1242/dmm.030411](https://doi.org/10.1242/dmm.030411)

License:
Creative Commons: Attribution (CC BY)

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (Harvard):
Haley, M, Mullard, G, Hollywood, K, Cooper, GJ, Dunn, W & Lawrence, C 2017, 'Adipose tissue, metabolic and inflammatory responses to stroke are altered in obese mice.', *Disease Models & Mechanisms*.
<https://doi.org/10.1242/dmm.030411>

[Link to publication on Research at Birmingham portal](#)

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Adipose tissue, metabolic and inflammatory responses to stroke are altered in obese mice

Michael J Haley¹, Graham Mullard^{2,3}, Katherine A. Hollywood^{2,3,4}, Garth J. Cooper^{2,3,5,6}, Warwick B. Dunn^{2,3,7}, Catherine B Lawrence¹

¹ Faculty of Biological, Medical and Human Sciences, University of Manchester, Manchester, United Kingdom, M13 9PT, UK.

² Centre for Endocrinology and Diabetes, Institute of Human Development, Faculty of Biological, Medical and Human Sciences, University of Manchester, Manchester, M13 9WL, UK.

³ Centre for Advanced Discovery and Experimental Therapeutics (CADET), Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, M13 9WL, UK.

⁴ School of Chemistry, Manchester Institute of Biotechnology, University of Manchester, 131 Princess Street, Manchester, M1 7DN, UK

⁵ Maurice Wilkins Centre for Molecular Biodiscovery, Faculty of Science, University of Auckland, Auckland 1020, New Zealand.

⁶ Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT, UK.

⁷ School of Biosciences and Phenome Centre Birmingham, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.

Corresponding author:

Dr C.B. Lawrence

Tel: +44 161 275 5253

E-mail: catherine.lawrence@manchester.ac.uk

KEY WORDS: Stroke, metabolomics, obesity, lipids, inflammation, adipokines

SUMMARY STATEMENT

Obesity, a co-morbidity for stroke, affected the acute metabolic and inflammatory response to stroke, highlighting the importance of considering comorbidities in preclinical stroke research, especially when identifying biomarkers.

ABSTRACT

Obesity is an independent risk factor for stroke, though several clinical studies have reported that obesity improves stroke outcome. Obesity is hypothesised to aid recovery by protecting against post-stroke catabolism. We therefore assessed whether obese mice had an altered metabolic and inflammatory response to stroke. Obese *ob/ob* mice underwent 20 min middle cerebral artery occlusion and 24 h reperfusion. Lipid metabolism and expression of inflammatory cytokines were assessed in the plasma, liver and adipose tissue. The obese-specific metabolic response to stroke was assessed in plasma using non-targeted UPLC-MS metabolomics coupled with univariate and multivariate analysis. Obesity had no effect on the extent of weight loss 24 h after stroke but affected the metabolic and inflammatory responses to stroke, predominantly affecting lipid metabolism. Specifically, obese mice had increases in plasma free fatty acids and expression of adipose lipolytic enzymes. Metabolomics identified several classes of metabolites affected by stroke in obese mice, including fatty acids and membrane lipids (glycerophospholipids, lysophospholipids and sphingolipids). Obesity also featured increases in inflammatory cytokines in the plasma and adipose tissue. Overall these results demonstrate that obesity affected the acute metabolic and inflammatory response to stroke and suggest a potential role for adipose tissue in this effect. These findings could have implications for longer-term recovery and also further highlight the importance of considering comorbidities in preclinical stroke research, especially when identifying biomarkers for stroke. However, further work is required to assess whether these changes translate into long-term effects on recovery.

INTRODUCTION

Obesity is a major health problem worldwide that is characterised by excessive fat accumulation, disruption of normal metabolic processes, and a state of chronic low-level inflammation. During obesity, adipocytes become stressed due to their energy storage capacity being exceeded, leading to adipose tissue inflammation. Rather than being simply a passive energy store, adipose tissue can release a wide variety of signalling molecules termed adipokines. Inflammation within the adipose tissue therefore leads to the release of pro-inflammatory mediators and adipokines into the circulation. Besides having an established role in immune regulation and energy balance, adipokines have been found to regulate an expanding array of physiological functions, including haemostasis, lipid and glucose metabolism, blood pressure, insulin sensitivity, and angiogenesis (Guri and Bassaganya-Riera, 2010; Trayhurn and Wood, 2005). Alterations in adipokine release may therefore affect the function of other organs important for metabolism, for example the liver.

Although being obese can result in several conditions that are associated with increased stroke risk including hypertension, diabetes and high cholesterol, obesity has now been identified as an independent risk factor for stroke (Strazzullo et al., 2010). However, some epidemiological studies in patients have reported a protective effect of obesity on stroke outcome, including reduced long-term mortality and improved functional recovery (Doehner et al., 2013; Vemmos et al., 2011). This so-called 'obesity paradox' may potentially be explained by design of the epidemiological studies, including complications arising from how obesity is measured, age, type and severity of stroke, and study design (Haley and Lawrence, 2016a). A biological hypothesis that has been proposed to explain the obesity paradox is that obesity may protect against the metabolic consequences of stroke (Scherbakov et al., 2011).

Weight loss after stroke is a common clinical observation and metabolic status post-stroke is an important determinant of outcome, with undernourishment worsening functional recovery and survival (FOOD Trial Collaboration, 2003). Impaired feeding behaviour and inactivity due to post-stroke paresis are thought to contribute to post-stroke weight loss and recommendations for dietary support of patients have been established (Lim and Choue, 2013). However, in both patients

and animals, stroke may also have more immediate and direct effects on energy balance via other more rapid mechanisms. Stroke results in an inflammatory response within the first 24 h at the site of ischaemia, systemically, and within peripheral organs (Denes et al., 2010a). This response involves induction of inflammatory cytokines such as interleukin-6 (IL-6), and the chemokines CCL2 (MCP-1) and CXCL1 (KC). Inflammatory cytokines have been implicated in the pathogenesis of cachexia, a condition featuring loss of lean and adipose tissue weight due to hypermetabolism (Kotler, 2000). Activation of the hypothalamic-pituitary-adrenal (HPA) axis is also a feature of stroke that may promote weight loss through enhanced sympathetic signalling (Fassbender et al., 1994; Mitchell, 1997). The resulting increase in catabolic drive can lead to a loss of adipose and muscle mass, potentially leading to a worse functional outcome due to a loss of muscle function in patients (Scherbakov and Doehner, 2011). Similar losses of muscle mass after stroke have been reported in mice (Desgeorges et al., 2015; Springer et al., 2014). Changes in metabolism may therefore have an important role to play post-stroke and potentially impact on pathophysiology and outcome.

Despite the importance of metabolic status in patient outcome, the metabolic response to stroke has undergone little preclinical or clinical investigation. Therefore, the study of global metabolism to understand metabolic differences associated with stroke and the influence of obesity on outcome is an important research area. Metabolomics is the holistic study of low molecular weight chemicals (metabolites) in biological systems. Metabolites are important biochemicals as they act as precursors for the synthesis of other biochemical (e.g. proteins, RNA, DNA) and cellular structures (e.g. cell walls). As metabolites are the substrates and by-products of cellular metabolism the quantitative collection of metabolites (defined as the metabolome) provides a sensitive and dynamic phenotypic snapshot of human health and disease (Dunn et al., 2011a; Patti et al., 2012). This phenotypic snapshot can be applied to understand pathophysiological processes or to identify biomarkers associated with disease risk, onset, progression and treatment. Recent studies in animal models and humans have applied metabolomic approaches to understand the molecular pathophysiology of stroke and have highlighted specific important areas of metabolism. These include specific changes in amino acids, fatty acids,

sphingolipids, and lysophospholipid species (Gao et al., 2013; Jové et al., 2015; Kimberly et al., 2013; Liu et al., 2015; Sheth et al., 2015; Zhu et al., 2015).

The aim of this study was to assess how the acute metabolic and inflammatory responses to stroke were affected by obesity. In obese mice prior to and 24 h post-stroke we assessed lipid metabolism and the expression of inflammatory mediators in metabolically active organs. The plasma metabolite profile was then assessed using non-targeted ultra-high performance liquid chromatography-mass spectrometry (UHPLC-MS) combined with univariate and multivariate analysis, allowing the metabolic response to stroke in obese mice to be identified.

RESULTS

Stroke alters lipid metabolism in obese mice

Both control *ob/-* and obese *ob/ob* mice lost a significant amount of body weight at 24 h after stroke, but there was no difference in the absolute weight loss between groups (Fig. 1A). However, when expressed as a percentage of pre-surgery weight, *ob/ob* mice lost significantly less weight. In both genotypes, no significant correlation was found between ischaemic damage and either absolute or percentage weight loss. Stroke resulted in significantly greater (108%) ischaemic damage in obese *ob/ob* compared to *ob/-* mice.

Blood glucose levels were significantly increased in obese *ob/ob* compared to control *ob/-* mice prior to surgery, and at 24 h post-stroke. Blood glucose concentrations were not affected by stroke in either control *ob/-* or obese *ob/ob* mice as no significant difference was observed between blood glucose concentrations at 24 h post-stroke when compared to pre-surgery values for obese *ob/ob* and control *ob/-* separately (Fig. 1B).

Obesity *per se* was associated with an increase in plasma FFA, as concentrations were significantly greater in naïve *ob/ob* mice. Stroke then resulted in a further increase in plasma FFA in *ob/ob* mice, with concentrations in obese mice being significantly increased relative to both naïve obese mice and control mice post-stroke

(Fig. 1Ci). Plasma glycerol was significantly increased in naïve obese *ob/ob* mice, but there was no effect of stroke in either control or obese mice (Fig. 1Cii).

In the epididymal adipose tissue of obese *ob/ob* mice, FFA were elevated in naïve mice, though after stroke there was a significant reduction in adipose FFA in obese *ob/ob* mice relative to controls (Fig. 1Di). No effect of genotype or treatment was observed in glycerol content in adipose tissue (Fig. 1Dii).

Liver triglycerides were significantly higher in naïve *ob/ob* mice compared to control *ob/-* mice, and remained significantly higher after stroke (Fig. 1Ei). However, stroke resulted in a significant increase in liver triglycerides in control *ob/-* mice only. Glycerol levels in the liver were significantly higher in naïve obese *ob/ob* mice. In response to stroke there was a significant reduction in liver glycerol in obese *ob/ob* mice but no change in control mice (Fig. Eii).

Obesity differentially affects expression of adipose lipolytic enzymes

The epididymal adipose tissue expression of the lipolytic enzymes ATGL, HSL, and the Ser563 phosphorylated form of HSL, were all similar between naïve control *ob/-* and obese *ob/ob* mice (Fig. 2). HSL expression in obese *ob/ob* mice was significantly increased 24 h after stroke, but remained unchanged in response to stroke in control *ob/-* mice (Fig. 2A). Conversely, expression of HSL Ser563 was significantly increased post-stroke in control *ob/-* mice, with no effect of stroke seen in obese *ob/ob* mice (Fig. 2B). The expression of ATGL was increased in adipose tissue 24 h post-stroke in obese *ob/ob* compared to naïve obese, but was unaffected by stroke in control *ob/-* mice (Fig. 2C).

Obesity alters the peripheral inflammatory response to stroke in the plasma, epididymal fat and liver

Ischaemic stroke increased expression of some inflammatory mediators as measured by cytometric bead array in the plasma, epididymal fat and liver (Fig. 3), and this increase was often greater in obese mice. In response to stroke, both obese *ob/ob* and control *ob/-* mice had significantly increased concentrations of plasma and

liver IL-6, plasma G-CSF and CXCL1 (Figs. 3A and C). However, there were significantly greater responses in obese mice in plasma IL-6, G-CSF and CXCL1, and liver CXCL1 increased in obese mice only. Furthermore, only obese mice showed an increase in inflammatory mediators in the adipose tissue after stroke (Fig. 3B). Obese mice showed increased expression of inflammatory mediators (IL-6, TNF α , ICAM-1) in the epididymal fat after ischaemic stroke, whereas there was no significant effect in control mice. Expression of CCL2 was significantly greater in the plasma, epididymal fat and liver of obese mice prior to stroke. However, stroke then resulted in a significant decrease in CCL2 expression in the plasma and both tissues.

Stroke reduced plasma concentrations of the adipokines resistin and adiponectin

The expression of the adipokines resistin and adiponectin were measured in the plasma and epididymal adipose tissue by ELISA (Fig. 3). In the epididymal adipose tissue in both naïve mice and post-stroke, obese *ob/ob* mice had significantly lower expression of both resistin and adiponectin (Fig. 3B). Similarly, resistin concentrations were lower in the plasma of naïve obese mice. Stroke then resulted in a significant decrease in plasma concentrations of both resistin and adiponectin (Fig. 3A). Post-stroke plasma concentrations of resistin were significantly lower in both genotypes, and there was a significant effect of treatment (pre- versus post-stroke) on adiponectin concentrations.

Untargeted metabolomics identified the obese-specific metabolic response to stroke

Samples were randomly analysed applying a UHPLC-MS platform, appropriate for the detection of a wide range of semi-hydrophilic and lipophilic metabolites. To calculate the quality of data acquired and to enable quality assurance of the data, a single quality control (QC) sample was intermittently analysed every 6th injection throughout the run. All metabolite features with a relative standard deviation > 20% and where there was greater than 30% missing values were removed from the

dataset prior to data analysis. This process removes poor quality data and 4891 and 3013 metabolite features remained in positive and negative ion mode, respectively post filtering.

Principal components analysis (PCA) was performed to assess the natural variation in the dataset (Fig. 4). The QC samples were tightly clustered compared to the biological samples highlighting the reproducibility of the data. The scores plot for negative ion mode data (Fig. 4A) showed a separation in principal component 2 (PC2) related to time; samples from naïve control *ob/-* and obese *ob/ob* mice were separated from samples from control *ob/-* and obese *ob/ob* mice 24 h post-stroke. For positive ion mode data (Fig. 4B), separation in PC1 based on control *ob/-* versus obese *ob/ob* animals was suspected though one sample in the obese 24 h post-stroke class was different to all other samples in the class, which masked this observation.

Supervised partial least squares-discriminant analysis was performed to identify multivariate groups of metabolites that discriminate between *ob/-* and *ob/ob* mice in naïve animals, and at 24 h post-stroke. Although validated models were observed when comparing control and obese animals pre-stroke (naïve), validated models were not constructed when comparing control and obese animals 24 h after stroke. Therefore further biological analysis of the variable importance in projection loadings was not performed.

Statistical analysis was performed to compare naïve control (*ob/-*) versus naïve obese (*ob/ob*) mice, and control versus obese animals 24 h post-stroke. False discovery rate (FDR) calculations were performed following the Benjamini–Hochberg procedure to limit FDR observations. 68 unique metabolites were observed to be statistically significant when naïve control mice were compared to naïve obese mice (Fig. 5A). Changes in amino acids, fatty acids, oxidised fatty acids, nucleotides, glycerophospholipids and lysophospholipids were observed and these results indicate metabolic changes related to obesity in the absence of stroke (Table 1). We then compared the metabolic profiles of control (*ob/-*) and obese (*ob/ob*) mice 24 h after stroke. Metabolites that were already found to be significantly altered by obesity in naïve animals were excluded from this list, and so the resulting metabolite profile is the obese-specific metabolic response to stroke. 83 unique metabolites, not

observed to be statistically significant between naïve control and obese mice, were found to be statistically significant when comparing control to obese mice 24 h after stroke (Fig. 5B). These metabolites included changes in amino acids, fatty acids, oxidised fatty acids, carbohydrates, ceramides and sphingolipids, sulphated metabolites, glycerophospholipids and lysophospholipids (Table 2). Metabolic pathway enrichment was also performed but showed no statistically significant enrichment, primarily because many software do not include lipid metabolism in significant detail.

Discussion

Stroke is known to affect metabolism in humans, with weight loss commonly reported in patients where it is associated with poor functional recovery (FOOD Trial Collaboration, 2003; Scherbakov and Doehner, 2011). In this context, the metabolic reserves found in obesity have been suggested to improve tolerance to post-stroke catabolism, therefore improving stroke survival and outcome (Scherbakov et al., 2011). Weight loss is also found in mice within the first 24 h post-stroke, though animals continue to lose weight for a number of days post-stroke (Dirnagl, 2010). However, the mediators of this catabolic drive have not been well characterised, though are hypothesised to include inflammatory mediators such as IL-6 and TNF α (Scherbakov et al., 2011). Previous studies in mice have demonstrated that there is an acute inflammatory response in the periphery after stroke, including in metabolically active tissues such as the liver and adipose tissue (Denes et al., 2010b; Offner et al., 2006; Wang et al., 2011a). Therefore, we characterised the acute (24 h) metabolic response to stroke and potential inflammatory mediators in the context of concurrent obesity (Fig. 6). We show for the first time that the metabolic response to stroke is different in obese compared to control mice. This observation was primarily related to lipid metabolism, which was also altered naïvely in obese animals. The altered metabolic response in obese animals was accompanied by increased cytokine expression in the liver and plasma, and an obese-specific inflammatory response in the adipose tissue.

The initial ischaemic insult in stroke is accompanied by a rapid induction of inflammatory cytokines and chemokines in the blood and peripheral organs (Chapman et al., 2009; Offner et al., 2006). Here, we found an increased plasma response in IL-6, CXCL1 and G-CSF in obese mice after stroke. Increases in plasma CXCL-1 have also been observed after stroke in diet-induced obese mice (Maysami et al., 2015). In patients, the magnitude of this IL-6 response correlates positively with stroke severity (Smith et al., 2004; Smith et al., 2006a). As *ob/ob* mice have worse outcome after experimental stroke, this increased peripheral immune response may be a cause or consequence of their increased ischaemic damage (Haley and Lawrence, 2016b; Mayanagi et al., 2008; McColl et al., 2010; Terao et al., 2008). An exception to the pattern of increased peripheral inflammation in *ob/ob* mice after stroke was the reduction in levels of CCL2 (MCP-1). Plasma CCL2 levels in *ob/ob* mice have been reported to be unaffected by obesity *per se*, but increased after stroke (Terao et al., 2008). However, previous reports in patients suggest that plasma CCL2 levels increase with obesity (Kim et al., 2006), potentially explaining the high basal levels found here, though the reason for the reduction in CCL2 after stroke in obese animals is unclear. Stroke also resulted in an inflammatory response in the fat of obese mice characterised by increased IL-6, TNF α and ICAM-1 expression. A similar pro-inflammatory response has been reported in rats and aged mice after MCAO, which is associated with deficits in insulin sensitivity (Shin et al., 2015; Wang et al., 2011a). Furthermore, surgical removal of visceral fat in aged mice prior to MCAO reduced lesion volume (Shin et al., 2015). How this protective effect is mediated is unclear, but highlights that the adipose tissue is not just a passive store of fat, but is a highly active endocrine organ. Indeed, the adipose tissue in obese humans becomes a potent source of inflammatory mediators, including IL-6 and IL-8 (the mouse homologue of IL-8 is CXCL1) (Fain, 2010). Therefore, the post-stroke plasma increases in IL-6 and CXCL1 found in obese mice here could be due to increased release from the adipose tissue.

Adipose tissue is also capable of releasing a growing list of factors termed adipokines. Here, we found a decrease in the adipose expression of both resistin and adiponectin in obese mice prior to stroke as has been previously reported in obesity (Fujinami et al., 2006; Kern et al., 2003). However, we found that stroke

resulted in a decrease in plasma resistin and adiponectin in both control and obese mice. As both resistin and adiponectin are exclusively released by adipocytes in mice (Banerjee and Lazar, 2003; Scherer et al., 1995), this suggests stroke can alter the release of adipokines from adipose tissue. Alterations in plasma adiponectin and resistin have both been implicated in stroke risk in patients (Efstathiou et al., 2005; Efstathiou et al., 2007), though adipokines more generally could affect stroke outcome by modulating the immune system, vasculature, and energy homeostasis (Guri and Bassaganya-Riera, 2010; Haley and Lawrence, 2016a; Trayhurn and Wood, 2005).

The accumulation of excess fat in obesity is known to affect lipid metabolism, however we found that stroke triggered a further effect on lipid metabolism in obese animals that was not seen in controls. This was characterised by an increase in plasma FFA, and decrease in epididymal fat FFA at 24 h post-stroke. Plasma FFA concentrations are tightly regulated by hormonal regulation to ensure tissues receive an appropriate supply of fatty acids for use as an energy source. However, fatty acids may also drive pathology, especially when concentrations remain inappropriately high (Frayn et al., 1996). The majority of FFAs in the plasma are derived from lipolysis of triglycerides within adipocytes (Frayn, 2012), suggesting an increase in lipolysis may underlie this increase in obese mice.

Stroke had differential effects on the expression and phosphorylation of lipolytic enzymes in control and obese mice. The activity of lipolytic enzymes in adipose tissue determines the rate of hormone-stimulated and basal lipolysis. In mice over 95% of triglyceride hydrolysis in adipocytes is due to the enzymes HSL and ATGL (Schweiger et al., 2006). In order to quickly respond to fluctuating energy requirements, HSL activity is usually mediated by phosphorylation, rather than by a change in protein expression (Anthonsen et al., 1998). Through this regulation, HSL activity is increased pre-prandially by β -adrenergic stimulation, and decreased post-prandially by insulin. After experimental stroke, obese mice had increased HSL expression but no change in Ser563 phosphorylation. Conversely, in control mice stroke had no effect on HSL expression, but increased Ser563 phosphorylation. This suggests that HSL was stimulated by hormonal exposure in control mice, but was affected by a different mechanism in obese mice.

Rather than being due to hormonal stimulation, increased circulating FFAs found in obese mice post-stroke may be due to increased expression of inflammatory mediators in the adipose tissue. TNF α has been shown to raise plasma FFA levels by acting on the adipose tissue and liver to stimulate basal lipolysis and reduce FFA reuptake (Chen et al., 2009). Pro-inflammatory mediators can increase basal lipolysis in adipocytes via NF- κ B and other inflammatory pathways, with the result being an increase in the rate of basal lipolysis independently of HSL phosphorylation (Doerrler et al., 1994; Grisouard et al., 2012; Langin and Arner, 2006). Furthermore, stimulation of lipolysis by the pro-inflammatory endotoxin lipopolysaccharide *in vivo* involves up-regulation of HSL expression without an increase in its phosphorylation (Osto et al., 2011). The increase in ATGL expression seen in obese mice also suggests an increase in basal lipolysis, since it is an important mediator of basal lipolysis in rodents (Langin et al., 2005; Zimmermann et al., 2004). Therefore, stroke may trigger an inflammatory response in the adipose tissue of obese mice that results in an increase in basal lipolysis, and thus in increased plasma FFA concentrations. This may be accompanied by a reduction in the clearance of FFAs from the plasma, which has previously been reported in obese patients (McQuaid et al., 2011).

As control *ob/-* and obese *ob/ob* mice appeared to show different metabolic responses to stroke, particularly in lipid metabolism, we decided to study metabolism at the whole organism level by applying non-targeted UHPLC-MS metabolomics. In this analysis, obesity *per se* in the absence of stroke affected several classes of metabolites in the plasma of *ob/ob* mice. These changes were not dependent on changes in diet composition as *ob/ob* mice become obese due to hyperphagia. In comparison, metabolomic studies using mice that are obese due to a high-fat diet have the caveat of not being able to differentiate effects occurring as a consequence of diet, from those occurring as a consequence of obesity (Duggan and Hittel, 2011). However, a potential caveat of using the obese *ob/ob* mouse in the current study is their lack of the adipokine leptin, which is known to modulate energy balance and the immune system (Trayhurn and Wood, 2005; Zhang et al., 1994).

A large number of the metabolites detected as being significantly affected by obesity in mice here were lipid related, with lipid species overall being increased in obese *ob/ob* mice, as expected. The largest proportion of these lipids was membrane-associated, including glycerophospholipids, lysophospholipids and sphingolipids. Lipidomics in humans has demonstrated that obesity generally increases the abundance of lipid species, and certain species have been found to correlate with body mass index (BMI) including acyl glycerides, phosphatidylethanolamines, phosphatidylcholines, and lysophospholipids species (Graessler et al., 2009; Oberbach et al., 2011; Wallace et al., 2014). Furthermore, several of the lysophospholipids species that increased in obese animals in the present study (specifically lysophosphatidylcholines [LysoPCs] 18:0, 18:1 and, 18:2) have been correlated with measures of insulin resistance and inflammation in patients (Wallace et al., 2014). Mice that develop obesity due to being fed a high-fat diet also showed increases in fatty acids, phosphatidylcholines and lysophospholipid species (Kim et al., 2011; Sampey et al., 2012). Two specific metabolite or metabolite classes which require further investigation are, sphinganine-1-phosphate (4 fold higher in naïve *ob/ob* mice) metabolites, and the metabolite class of plasmalogens. The sphinganine-1-phosphate related metabolite sphingosine-1-phosphate has been implicated in poor outcome for ischemic stroke (Ichijo et al., 2015; Maceyka et al., 2013; Moon et al., 2015), and therefore sphingolipid metabolism before and after stroke is worthy of investigation. Plasmalogens are identifiable by their ether linkage at the sn-1 position, and can make up 20% of all glycerophosphocholines in the brain (Farooqui and Horrocks, 2001). Plasmalogens have numerous important roles in the central nervous system, including protecting against reactive oxygen species damage, thus seeing specific metabolites both increased and decreased could be relevant for subsequent stroke outcome.

Beyond effects on lipid metabolism, changes in other metabolites in *ob/ob* mice were suggestive of health complications usually associated with obesity. Obese mice had increases in the amino acids leucine and phenylalanine. In patients, these were found to predict future diabetes and correlate positively with BMI (Gralka et al., 2015; Ho et al., 2016; Shah et al., 2012; Wang et al., 2011b). Obese *ob/ob* mice also

had reduced plasma arginine, being the most greatly reduced (7 fold) metabolite species detected. Similar findings of reduced plasma arginine have been made in genetically obese Zucker rats (Serkova et al., 2006). Reductions in plasma arginine have been implicated in the development of cardiovascular disease (Shah et al., 2012; Tang and Wang, 2009), potentially because arginine deficiency can result in endothelial dysfunction and decreased nitric oxide availability (Morris, 2012). Arginine and associated metabolic products have also been demonstrated to be acutely elevated post stroke, so the potential impact of reduced arginine found in obese subjects on subsequent stroke outcome requires further study (Molnar et al., 2014). Furthermore, in obese mice a reduction in a carbohydrate deoxy-glucose species was observed, which may correspond to 1,5-anhydroglucitol, a marker of prolonged hyperglycaemia and predictor of future diabetes (Dungan et al., 2006). Overall, the metabolite profile of *ob/ob* mice shows biomarkers not only of obesity, but also aspects of the metabolic syndrome, including insulin resistance, dyslipidaemia and cardiovascular disease. This suggests the obese *ob/ob* mice possess a spectrum of risk factors for stroke similar to those seen in obese patients.

Metabolomic analysis of metabolites in the plasma at 24 h post-stroke was performed in both obese *ob/ob* and control mice. A comparison of these two profiles found 83 unique metabolites to be significantly affected by obesity after stroke. As this list excluded metabolites detected as being affected by obesity in the absence of stroke, this list entails the obese-specific metabolic response to stroke. A large number of these species were lipid-related, including several classes of membrane lipids. Further changes in glycerophospholipids and lysophospholipids were found in addition to those altered by obese mice in the absence of stroke. LysoPC(20:4) was increased in obese mice relative to control mice after stroke, and is a reported biomarker of ischaemic stroke in patients (Jové et al., 2015; Zhu et al., 2015). Stroke also affected long chain sphingomyelin (SM) sphingolipids in obese animals. Two species increased in obese mice after stroke, SM(d18:1/18:0) and SM(d18:1/18:1), were found to be specific markers of acute traumatic and ischaemic brain injury in mice (Sheth et al., 2015). Sphingomyelin lipids also correlated positively with plasma IL-8 and TNF α in obese subjects (Wallace et al., 2014), and are implicated in the development of cardiovascular disease due to their promotion of pro-inflammatory signalling pathways (Nixon, 2009; Sun et al., 2016). Therefore, the upregulation of

sphingomyelins in response to stroke was specific to obese mice, and may be a marker of post-stroke inflammation or greater damage in obese mice. Alternatively, sphingolipid species may be worsening outcome by activating pro-inflammatory signalling pathways (Sun et al., 2016). The increase in oxidised forms of fatty acids similar to those found abundantly in obese *ob/ob* adipose tissue (long chain fatty acids, C₁₄ to C₁₈) suggests that fatty acids liberated by lipolysis in obese mice after stroke are undergoing incomplete β -oxidation to be used as an energy source.

The differences in the metabolic response to stroke between obese and control animals were not restricted to lipid species, with several classes of non-lipid metabolites also significantly affected. Corticosterone was significantly higher in obese animals after stroke, suggestive of increased HPA axis activation. Activation of the HPA axis results in the release of catecholamines and glucocorticoids that can directly stimulate lipolysis, and thus affect plasma lipid concentrations. Amino acids were also affected, with obese animals showing reductions in tyrosine and methionine, and an increase in taurine. Similar changes in plasma amino acids have been reported as biomarkers for ischaemic stroke in both patients and rodents, though the directions of these changes vary (Gao et al., 2013; Kimberly et al., 2013; Liu et al., 2015; Zhu et al., 2015). As the extent of these changes can correlate with the severity of ischaemic damage (Kimberly et al., 2013), the difference between obese and control animals found here could be due to increased ischaemic damage in obese mice.

Weight loss for several days after experimental stroke is common in rodents, and often correlates with stroke severity (Dirnagl, 2010). In the current study, absolute weight loss was similar between obese and control mice, though obese mice lost less weight as a percentage of baseline weight. There was also no correlation between either measure of weight loss and ischaemic damage. However, it unclear from what compartment this weight is being lost at this acute time point. For example, weight may be lost not only from adipose tissue, but potentially from glycogen stores, muscle or other lean stores. Therefore, weight loss at this acute time point may not reflect long-term changes in metabolism. In order to assess the acute metabolic response to stroke, we selected an acute time point that is less likely to be affected by other complications of stroke such as inactivity and motor deficits. However, future work is required to establish whether acute changes in metabolism

translate into longer-term changes in metabolism and outcome, but data here suggest that weight changes in obese mice are likely to be altered.

In the present study, obesity affected the metabolic response to stroke, characterised by an increase in plasma FFAs, likely due to an increase in basal lipolysis. Metabolomics revealed that the obese-specific response to stroke featured changes in various lipid species, including acyl glycerides, sphingolipids, glycerophospholipids, lysophospholipids and fatty acids derivatives. This altered metabolic response to stroke may be driven by or may drive a post-stroke inflammatory response in the adipose tissue of obese mice that was not seen in control mice. The adipose tissue has previously undergone little investigation in the response to stroke, though may affect outcome due its ability to release adipokines and pro-inflammatory cytokines. These differences in the metabolic and inflammatory responses to stroke in obese mice highlights the importance of considering comorbidities in preclinical studies, especially when considering the usefulness of biomarkers of stroke. It will also be important to consider how obesity affects the loss of muscle mass after stroke, as this will be an important determinant of functional recovery, though pro-inflammatory cytokines are known to promote catabolism that can lead to sarcopenia (Kotler, 2000). Overall, whether these results support the hypothesis that obesity protects against post-stroke weight loss will depend on whether these acute changes in lipolysis, inflammation and metabolism translate into longer-term effects on recovery or outcome.

MATERIALS AND METHODS

Mice

Experiments were performed on 16 to 19 week-old male obese *ob/ob* (C57BL/6OlaHsd-Lep^{ob}, *n* = 26) or male heterozygote *ob/-* control mice (*n* = 26; Harlan-Olac, UK). Body weight at the time of surgery was 32.5 ± 5.7 g for control (*ob/-*) and 54.1 ± 6.0 g for obese (*ob/ob*). All mice were housed in standard conditions (temperature of $20 \pm 2^\circ\text{C}$; humidity, $55\% \pm 5\%$; 12-hour light/12-hour dark cycle with lights on at 08:00 hours) and were given *ad libitum* access to a standard laboratory

diet (RM1, Special Diet Services, UK) and water. All experimental procedures using animals were conducted in accordance with the United Kingdom Animals (Scientific Procedures) Act, 1986 and approved by the Home Office and the local Animal Ethical Review Group, University of Manchester.

Focal cerebral ischaemia

Focal cerebral ischaemia was induced in control (*ob/-*) and obese (*ob/ob*) mice by transient (20 min) middle cerebral artery occlusion (MCAO). We have previously published that this approach and duration of occlusion leads to worse outcome in *ob/ob* mice, and this was confirmed in a subset of animals in this study ($n = 6$ per group) (Haley and Lawrence, 2016b). Briefly, under isoflurane anaesthesia, the carotid arteries were exposed and a silicone coated filament (coating 210 μm in diameter and ≥ 5 mm length, Doccol, USA) was introduced into the external carotid artery and advanced along the internal carotid artery until occluding the origin of the MCA. Successful MCAO was confirmed by a reduction in cerebral blood flow of at least 80% as measured using laser-Doppler (Moor Instruments, UK). After 20 min, the filament was withdrawn to establish reperfusion and the wound sutured. During surgery, core body temperature was monitored using a rectal probe and maintained at 37°, using a homeothermic blanket (Harvard Apparatus, Kent, UK). Animals were allowed to recover and at 24 h later they were weighed and re-anesthetised. Cardiac blood was collected (with sodium citrate to prevent clotting), spun at 1400 g for 10 min at 4°C and aliquots of plasma were immediately frozen. Samples of liver and epididymal fat pads were also taken for homogenisation in buffer (50 mM Tris-HCL, 150 mM NaCl, 5 mM CaCl_2 , 0.02% NaN_3 , 1% Triton X-100). Naïve animals ($n = 10$ per genotype) were treated identically, but underwent no experimental ischaemia. All animals were randomly assigned to a treatment group (cerebral ischaemia versus naïve). In each of the control *ob/-* and obese *ob/ob* stroke groups 16 animals underwent surgery, with 2 animals excluded from each group due to subarachnoid haemorrhage or death based on pre-established criteria (final $n = 14$ per genotype).

Quantification of cytokines

Concentrations of cytokines were measured in tissue homogenates or plasma samples by cytometric bead array (CBA) as defined by the manufacturer's instructions, with Flex Sets used for IL-6, tumor necrosis factor α (TNF α), CCL2, CXCL1 and granulocyte-colony stimulating factor (G-CSF; BD-Biosciences). Intracellular adhesion molecule (ICAM-1), adiponectin and resistin were measured in epididymal fat homogenates or plasma samples by ELISA according to the manufacturer's instructions (DuoSet, R&D Systems).

Glucose, free fatty acid, glycerol and triglyceride measurement

Blood glucose was measured in tail vein blood samples taken immediately prior to experimental ischaemia or at time of sacrifice using a hand-held glucose monitor (Accu-Chek Aviva, Roche, UK). FFAs and glycerol were quantified in cardiac plasma samples and epididymal adipose tissue homogenates, and triglycerides and glycerol in liver homogenates, as per manufacturer's instructions using commercially available kits (Zen Bio, USA).

Adipose tissue HSL and ATGL assays

Expression of hormone sensitive lipase (HSL), its serine-563 phosphorylated form (HSL Ser563), and adipose triglyceride lipase (ATGL) were measured in epididymal fat pad homogenates by Western blot. Antibodies for immunoblotting were as follows: anti-HSL (1:2000, Cell Signalling Technology, USA), anti-HSL Ser563 (1:500, Cell Signalling Technology), anti-ATGL (1:2000, Cell Signalling Technology), and anti- β -actin (1:5000, Sigma). Epididymal adipose tissue homogenates (25 μ g total protein per well) were separated by SDS page, and proteins transferred to a polyvinylidene fluoride membrane. Membranes were then blocked [5% milk and 0.1% TWEEN-20 in PBS (PBS-T)], and incubated at 4°C overnight in primary antibodies diluted in 1% BSA in PBS-T. After being incubated with HRP-conjugated secondary antibodies (1:500, Wako Chemicals) in 5% milk in PBS-T, blots were developed using an Enhanced Chemiluminescent Detection Kit (GE Healthcare).

Digital images of protein bands were acquired (ImageQuant 350, GE Healthcare, UK) and semi-quantitative analysis of protein content performed by densitometry using ImageQuant TL software (GE Healthcare, UK), with values normalised to β -actin as a loading control.

Non-targeted metabolomics

Mouse plasma was taken from control *ob/-* and obese *ob/ob* mice without previous treatment (naïve, $n = 5-6/\text{group}$) and at 24 h post-stroke ($n = 6-8/\text{group}$), and prepared as previously described (Dunn et al., 2011b). Plasma was thawed on ice and deproteinised by addition of 300 μL of methanol to 100 μL of plasma followed by vortex mixing (15 sec) and centrifugation (13,365 g for 15 min). The supernatants (300 μL) were transferred to 2.0 mL centrifuge tubes and vacuum dried. Prior to analysis the dried extracts was reconstituted in 100 μL of 50/50 water/methanol. Additionally, pooled quality control (QC) samples were prepared by pooling 75 μL aliquots of each biological sample, subsequently 100 μL aliquots were deproteinised, dried and reconstituted as described above.

Samples were analysed twice (in positive ion and negative ion modes) applying an Accela UHPLC system interfaced to an electrospray LTQ-Orbitrap Velos hybrid mass spectrometer (ThermoFisher Scientific, Hemel Hempstead, UK). Chromatographic separations were performed on a Hypersil GOLD column (100 x 2.1 mm, 1.9 μm ; Thermo Fisher Scientific, Runcorn, UK) operating at a column temperature of 50°C. A binary gradient elution was applied at a flow rate of 400 $\mu\text{L} \cdot \text{min}^{-1}$ with two solvents; Solvent A = 0.1% formic acid in water (vol/vol) and solvent B = 0.1% formic acid in methanol (vol/vol). Solvent A was held at 100% for 0.5 min followed by an increase to 100% solvent B over 15.5 min, which was then held at 100% solvent B for a further 5 min. A step change to 100% solvent A was performed at 20.5 min and then held at 100% solvent A to equilibrate for 1.5 min. All column eluent was transferred to the mass spectrometer and full-scan profiling data were acquired in the m/z range 100-1000 in the Orbitrap mass analyser (mass resolution 30,000; Full Width Half Maximum at $m/z = 400$). The source and ion transfer parameters applied were as follows; source heater = 200°C, sheath gas = 50 (arbitrary units), aux gas = 15 (arbitrary units), capillary temperature = 300°C,

ISpray voltage = 4kV (positive-ion mode) and 3kV (negative-ion mode), s lens = 65% and AGC = 5×10^5 .

Raw instrument data were converted to netCDF file format with FileConverter software available in XCalibur (ThermoFisher Scientific, Bremen, Germany). Deconvolution was performed using the freely available XCMS software as described previously (Dunn et al., 2011b; Smith et al., 2006b). Data were exported from XCMS as a .csv file for further data analysis. The quality of data was assessed applying quality control (QC) data as previously described (Smith et al., 2006b), with all metabolite features with a RSD>20% or with greater than 30% missing values for QC samples being removed from the dataset prior to data analysis. Metabolite annotation was performed applying the PUTMEDID_LCMS workflow as previously described (Brown et al., 2011). All metabolite annotations are reported at level 2 according to MSI reporting standards (Sumner et al., 2007). The processed data was analysed in R with the univariate t-test applying the Benjamini–Hochberg procedure for false discovery rate calculation ($q<0.05$) after normalisation to total peak area. The fold change was calculated applying the median response per class with 95% confidence limits. The processed data were also analysed applying unsupervised Principal Components Analysis (PCA) and pairwise comparisons of classes applying supervised PLS-DA; both of these analyses were performed in the open access software MetaboAnalyst (Xia et al., 2012). Metabolites were manually clustered into classes defining similar chemical structure or metabolic pathway to identify biologically relevant and robust metabolic changes.

Statistical analyses

All ex vivo analyses were performed blinded to treatment (naïve or MCAO) and genotype (control or obese). Sample sizes were determined by power calculation ($\alpha = 0.05$, $\beta = 0.2$) of our previous data. Statistical analyses for all non-metabolomics data were performed using GraphPad software (GraphPad Software Inc., La Jolla, CA, USA). Data was tested for equal variance using the Brown–Forsythe and Bartlett's tests, and appropriate transformations applied if necessary. Two-way ANOVA was used for comparisons by genotype and by treatment followed by a

Šídák correction for multiple comparisons, and a *t*-test was used for two groups. Correlations between body weight loss and ischaemic damage were assessed by Pearson correlation coefficient. All data (apart from metabolomics) are represented as mean \pm standard error of the mean (s.e.m). $P < 0.05$ was considered significant.

Acknowledgements

We would like to thank the Biological Services Facility at the University of Manchester for expert animal husbandry husbandry and Paul Begley from the Centre for Advanced Discovery and Experimental Therapeutics (CADET), for technical support.

Competing interests

No contributing authors have any competing financial interests in relation to the work described.

Author Contributions

The conception and design of the study was performed by CBL and MJH. MJH performed all experimental *in vivo* work and data analysis. WBD, GM and KAH performed the untargeted metabolomics study. MJH, GJC, WBD and CBL were involved in the interpretation of data, and drafting of the manuscript.

Funding

This work was supported by the Medical Research Council (G1000399-1/1), Wellcome Trust (WT087512MA) and the Kohn Foundation.

References

- Anthonsen, M., Rönstrand, L., Wernstedt, C., Degerman, E. and Holm, C.** (1998). Identification of Novel Phosphorylation Sites in Hormone-sensitive Lipase That Are Phosphorylated in Response to Isoproterenol and Govern Activation Properties in Vitro. *J. Biol. Chem.* **273**, 215–221.
- Banerjee, R. R. and Lazar, M. a** (2003). Resistin: molecular history and prognosis. *J. Mol. Med. (Berl)*. **81**, 218–26.
- Brown, M., Wedge, D. C., Goodacre, R., Kell, D. B., Baker, P. N., Kenny, L. C., Mamas, M. a, Neyses, L. and Dunn, W. B.** (2011). Automated workflows for accurate mass-based putative metabolite identification in LC/MS-derived metabolomic datasets. *Bioinformatics* **27**, 1108–12.
- Chapman, K. Z., Dale, V. Q., Dénes, Á., Bennett, G., Rothwell, N. J., Allan, S. M. and McColl, B. W.** (2009). A rapid and transient peripheral inflammatory response precedes brain inflammation after experimental stroke. *J. Cereb. Blood Flow Metab.* **29**, 1764–1768.
- Chen, X., Xun, K., Chen, L. and Wang, Y.** (2009). TNF-alpha, a potent lipid metabolism regulator. *Cell Biochem. Funct.* **27**, 407–16.
- Denes, A., Thornton, P., Rothwell, N. J. and Allan, S. M.** (2010a). Inflammation and brain injury: Acute cerebral ischaemia, peripheral and central inflammation. *Brain Behav. Immun.* **24**, 708–723.
- Denes, A., McColl, B. W., Leow-Dyke, S. F., Chapman, K. Z., Humphreys, N. E., Grecis, R. K., Allan, S. M. and Rothwell, N. J.** (2010b). Experimental stroke-induced changes in the bone marrow reveal complex regulation of leukocyte responses. *J. Cereb. Blood Flow Metab.* **31**, 1036–1050.
- Desgeorges, M. M., Devillard, X., Toutain, J., Divoux, D., Castells, J., Bernaudin, M., Touzani, O. and Freyssenet, D. G.** (2015). Molecular mechanisms of skeletal muscle atrophy in a mouse model of cerebral ischemia. *Stroke*. **46**, 1673–1680.
- Dirnagl, U.** (2010). Complexities, Confounders, and Challenges in Experimental Stroke Research: A Checklist for Researchers and Reviewers. In *Rodent Models of Stroke* (ed. Dirnagl, U.), pp. 263–277. Totowa, NJ: Humana Press.

- Doehner, W., Schenkel, J., Anker, S. D., Springer, J. and Audebert, H. J.** (2013). Overweight and obesity are associated with improved survival, functional outcome, and stroke recurrence after acute stroke or transient ischaemic attack: observations from the TEMPiS trial. *Eur. Heart J.* **34**, 268–77.
- Doerrler, W., Feingold, K. R. and Grunfeld, C.** (1994). Cytokines induce catabolic effects in cultured adipocytes by multiple mechanisms. *Cytokine* **6**, 478–84.
- Duggan, G. and Hittel, D.** (2011). Differentiating short- and long-term effects of diet in the obese mouse using ¹H-nuclear magnetic resonance metabolomics. *Diabetes. Obes. Metab.* 859–862.
- Dungan, K. M., Buse, J. B., Largay, J., Kelly, M. M., Button, E. a, Kato, S. and Wittlin, S.** (2006). 1,5-Anhydroglucitol and Postprandial Hyperglycemia As Measured By Continuous Glucose Monitoring System in Moderately Controlled Patients With Diabetes. *Diabetes Care* **29**, 1214–9.
- Dunn, W. B., Broadhurst, D. I., Atherton, H. J., Goodacre, R. and Griffin, J. L.** (2011a). Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. *Chem. Soc. Rev.* **40**, 387–426.
- Dunn, W. B., Broadhurst, D., Begley, P., Zelena, E., Francis-McIntyre, S., Anderson, N., Brown, M., Knowles, J. D., Halsall, A., Haselden, J. N., et al.** (2011b). Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. *Nat. Protoc.* **6**, 1060–83.
- Efstathiou, S., Tsioulos, D. I., Tsiakou, A. G., Gratsias, Y. E., Pefanis, A. V and Mountokalakis, T. D.** (2005). Plasma adiponectin levels and five-year survival after first-ever ischemic stroke. *Stroke* **36**, 1915–1919.
- Efstathiou, S., Tsiakou, A. G., Tsioulos, D. I., Panagiotou, T. N., Pefanis, A. V, Achimastos, A. D. and Mountokalakis, T. D.** (2007). Prognostic significance of plasma resistin levels in patients with atherothrombotic ischemic stroke. *Clin. Chim. Acta.* **378**, 78–85.
- Fain, J. N.** (2010). Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review. *Mediat. Inflamm* **2010**, 513948.

- Farooqui, a a and Horrocks, L. a** (2001). Plasmalogens: workhorse lipids of membranes in normal and injured neurons and glia. *Neuroscientist* **7**, 232–245.
- Fassbender, K., Schmidt, R., Mossner, R., Daffertshofer, M. and Hennerici, M.** (1994). Pattern of activation of the hypothalamic-pituitary-adrenal axis in acute stroke. Relation to acute confusional state, extent of brain damage, and clinical outcome. *Stroke* **25**, 1105–1108.
- FOOD Trial Collaboration** (2003). Poor nutritional status on admission predicts poor outcomes after stroke: observational data from the FOOD trial. *Stroke* **34**, 1450–6.
- Frayn, K. N.** (2012). Organs and tissues. In *Metabolic Regulation: A Human Perspective*, pp. 92–143. Wiley-Blackwell.
- Frayn, K., Williams, C. and Arner, P.** (1996). Are increased plasma non-esterified fatty acid concentrations a risk marker for coronary heart disease and other chronic diseases? *Clin. Sci.* **90**, 243–253.
- Fujinami, A., Ohta, K., Matsui, H., Kitada, N., Kituara, Y., Kawahara, Y., Obayashi, H., Kuno, S., Nakamura, N. and Ohta, M.** (2006). Resistin Concentrations in Murine Adipose Tissue and Serum Measured by a New Enzyme Immunoassay. *Obesity* **14**, 199–205.
- Gao, J., Yang, H., Chen, J., Fang, J., Chen, C., Liang, R., Yang, G., Wu, H., Wu, C. and Li, S.** (2013). Analysis of serum metabolites for the discovery of amino acid biomarkers and the effect of galangin on cerebral ischemia. *Mol. Biosyst.* **9**, 2311–21.
- Graessler, J., Schwudke, D., Schwarz, P. E. H., Herzog, R., Shevchenko, A. and Bornstein, S. R.** (2009). Top-down lipidomics reveals ether lipid deficiency in blood plasma of hypertensive patients. *PLoS One* **4**, e6261.
- Gralka, E., Luchinat, C., Tenori, L., Ernst, B., Thurnheer, M. and Schultes, B.** (2015). Metabolomic fingerprint of severe obesity is dynamically affected by bariatric surgery in a procedure-dependent manner. *Am. J. Clin. Nutr.* **102**, 1313–1322.
- Grisouard, J., Bouillet, E., Timper, K., Radimerski, T., Dembinski, K., Frey, D. M., Peterli, R., Zulewski, H., Keller, U., Müller, B., et al.** (2012). Both

inflammatory and classical lipolytic pathways are involved in lipopolysaccharide-induced lipolysis in human adipocytes. *Innate Immun.* **18**, 25–34.

Guri, A. J. and Bassaganya-Riera, J. (2010). Systemic Effects of White Adipose Tissue Dysregulation and Obesity-Related Inflammation. *Obesity*.

Haley, M. J. and Lawrence, C. B. (2016a). Obesity and stroke: Can we translate from rodents to patients? *J. Cereb. Blood Flow Metab.* [Epub ahead of print].

Haley, M. J. and Lawrence, C. B. (2016b). The blood-brain barrier after stroke: Structural studies and the role of transcytotic vesicles. *J. Cereb. Blood Flow Metab.* 0271678X16629976.

Ho, J. E., Larson, M. G., Ghorbani, A., Cheng, S., Chen, M. H., Keyes, M., Rhee, E. P., Clish, C. B., Vasan, R. S., Gerszten, R. E., et al. (2016). Metabolomic profiles of body mass index in the framingham heart study reveal distinct cardiometabolic phenotypes. *PLoS One* **11**, 1–16.

Ichijo, M., Ishibashi, S., Li, F., Yui, D., Miki, K., Mizusawa, H. and Yokota, T. (2015). Sphingosine-1-phosphate receptor-1 selective agonist enhances collateral growth and protects against subsequent stroke. *PLoS One* **10**, 1–19.

Jové, M., Mauri-Capdevila, G., Suárez, I., Cambray, S., Sanahuja, J., Quílez, A., Farré, J., Benabdelhak, I., Pamplona, R., Portero-Otín, M., et al. (2015). Metabolomics predicts stroke recurrence after transient ischemic attack. *Neurology* **84**, 36–45.

Kern, P. A., Gregorio, G. B. Di, Lu, T., Rassouli, N. and Ranganathan, G. (2003). Adiponectin Expression From Human Adipose Tissue. Relation to Obesity, Insulin Resistance, and Tumor Necrosis Factor Expression. *Diabetes* **52**, 1779–1785.

Kim, C. S., Park, H. S., Kawada, T., Kim, J. H., Lim, D., Hubbard, N. E., Kwon, B. S., Erickson, K. L. and Yu, R. (2006). Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. *Int. J. Obes.* **30**, 1347–1355.

Kim, H.-J., Kim, J. H., Noh, S., Hur, H. J., Sung, M. J., Hwang, J.-T., Park, J. H., Yang, H. J., Kim, M.-S., Kwon, D. Y., et al. (2011). Metabolomic analysis of livers and serum from high-fat diet induced obese mice. *J. Proteome Res.* **10**,

- Kimberly, W. T., Wang, Y., Pham, L., Furie, K. L. and Gerszten, R. E.** (2013). Metabolite profiling identifies a branched chain amino acid signature in acute cardioembolic stroke. *Stroke*. **44**, 1389–95.
- Kotler, D.** (2000). Cachexia. *Ann. Intern. Med.* **133**, 622–634.
- Langin, D. and Arner, P.** (2006). Importance of TNFalpha and neutral lipases in human adipose tissue lipolysis. *Trends Endocrinol. Metab.* **17**, 314–20.
- Langin, D., Dicker, A. and Tavernier, G.** (2005). Adipocyte lipases and defect of lipolysis in human obesity. *Diabetes* **54**,.
- Lim, H. and Choue, R.** (2013). Impact of nutritional status and dietary quality on stroke: do we need specific recommendations? *Eur. J. Clin. Nutr.* **67**, 548–54.
- Liu, M., Zhou, K., Li, H., Dong, X., Tan, G., Chai, Y., Wang, W. and Bi, X.** (2015). Potential of serum metabolites for diagnosing post-stroke cognitive impairment. *Mol. BioSyst.* **11**, 3287–3296.
- Maceyka, M., Harikumar, K. B., Milstien, S. and Spiegel, S.** (2013). Sphingosine-1-phosphate signaling and its role in disease. **22**, 50–60.
- Mayanagi, K., Katakam, P. V., Gaspar, T., Domoki, F. and Busija, D. W. C.-** **2632795** (2008). Acute treatment with rosuvastatin protects insulin resistant (C57BL/6J ob/ob) mice against transient cerebral ischemia. *J Cereb Blood Flow Metab* **28**, 1927–1935.
- Maysami, S., Haley, M. J., Gorenkova, N., Krishnan, S., McColl, B. W. and Lawrence, C. B.** (2015). Prolonged diet-induced obesity in mice modifies the inflammatory response and leads to worse outcome after stroke. *J. Neuroinflammation* **12**, 140.
- McColl, B. W., Rose, N., Robson, F. H., Rothwell, N. J. and Lawrence, C. B.** (2010). Increased brain microvascular MMP-9 and incidence of haemorrhagic transformation in obese mice after experimental stroke. *J. Cereb. Blood Flow Metab.* **30**, 267–72.
- McQuaid, S., Hodson, L. and Neville, M.** (2011). Downregulation of adipose tissue fatty acid trafficking in obesity: a driver for ectopic fat deposition? *Diabetes* **60**, 47–55.

- Mitchell, A.** (1997). Clinical implications of poststroke hypothalamo-pituitary adrenal axis dysfunction: A critical literature review. *J. Stroke Cerebrovasc. Dis.* **6**, 377–88.
- Molnar, T., Pusch, G., Papp, V., Feher, G., Szapary, L., Biri, B., Nagy, L., Keki, S. and Illes, Z.** (2014). The L-arginine pathway in acute ischemic stroke and severe carotid stenosis: Temporal profiles and association with biomarkers and outcome. *J. Stroke Cerebrovasc. Dis.* **23**, 2206–2214.
- Moon, E., Han, J. E., Jeon, S., Ryu, J. H., Choi, J. W. and Chun, J.** (2015). Exogenous S1P Exposure Potentiates Ischemic Stroke Damage That Is Reduced Possibly by Inhibiting S1P Receptor Signaling. *Mediators Inflamm.* **2015**, 11–14.
- Morris, S. M.** (2012). Arginases and arginine deficiency syndromes. *Curr. Opin. Clin. Nutr. Metab. Care* **15**, 64–70.
- Nixon, G. F.** (2009). Sphingolipids in inflammation: pathological implications and potential therapeutic targets. *Br. J. Pharmacol.* **158**, 982–93.
- Oberbach, A., Bl, M., Wirth, H., Till, H., Kovacs, P., Kullnick, Y., Schlichting, N., Tomm, J. M., Rolle-kampczyk, U., Murugaiyan, J., et al.** (2011). Combined Proteomic and Metabolomic Profiling of Serum Reveals Association of the Complement System with Obesity and Identifies Novel Markers of Body Fat Mass Changes. 4769–4788.
- Offner, H., Subramanian, S., Parker, S. M., Afentoulis, M. E., Vandenbark, A. a and Hurn, P. D.** (2006). Experimental stroke induces massive, rapid activation of the peripheral immune system. *J. Cereb. Blood Flow Metab.* **26**, 654–665.
- Osto, M., Zini, E., Franchini, M., Wolfrum, C., Guscetti, F., Hafner, M., Ackermann, M., Reusch, C. E. and Lutz, T. a** (2011). Subacute endotoxemia induces adipose inflammation and changes in lipid and lipoprotein metabolism in cats. *Endocrinology* **152**, 804–15.
- Patti, G. J., Yanes, O. and Siuzdak, G.** (2012). Innovation: Metabolomics: the apogee of the omics trilogy. *Nat. Rev. Mol. Cell Biol.* **13**, 263–269.
- Sampey, B. P., Freerman, A. J., Zhang, J., Kuan, P.-F., Galanko, J. a, O'Connell, T. M., Ilkayeva, O. R., Muehlbauer, M. J., Stevens, R. D.,**

- Newgard, C. B., et al.** (2012). Metabolomic profiling reveals mitochondrial-derived lipid biomarkers that drive obesity-associated inflammation. *PLoS One* **7**, e38812.
- Scherbakov, N. and Doehner, W.** (2011). Sarcopenia in stroke-facts and numbers on muscle loss accounting for disability after stroke. *J. Cachexia. Sarcopenia Muscle* **2**, 5–8.
- Scherbakov, N., Dirnagl, U. and Doehner, W.** (2011). Body weight after stroke: lessons from the obesity paradox. *Stroke*. **42**, 3646–50.
- Scherer, P. E., Williams, S., Fogliano, M., Baldini, G. and Lodish, H. F.** (1995). A novel serum protein similar to C1q, produced exclusively in adipocytes. *J. Biol. Chem.* **270**, 26746–26749.
- Schweiger, M., Schreiber, R., Haemmerle, G., Lass, A., Fledelius, C., Jacobsen, P., Tornqvist, H., Zechner, R. and Zimmermann, R.** (2006). Adipose triglyceride lipase and hormone-sensitive lipase are the major enzymes in adipose tissue triacylglycerol catabolism. *J. Biol. Chem.* **281**, 40236–41.
- Serkova, N. J., Jackman, M., Brown, J. L., Liu, T., Hirose, R., Roberts, J. P., Maher, J. J. and Niemann, C. U.** (2006). Metabolic profiling of livers and blood from obese Zucker rats. *J. Hepatol.* **44**, 956–62.
- Shah, S. H., Kraus, W. E. and Newgard, C. B.** (2012). Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function. *Circulation* **126**, 1110–20.
- Sheth, S. A., Iavarone, A. T., Liebeskind, D. S., Won, S. J. and Swanson, R. A.** (2015). Targeted lipid profiling discovers plasma biomarkers of acute brain injury. *PLoS One* **10**, 1–15.
- Shin, J. a., Jeong, S. I., Kim, M.-S., Yoon, J. C., Kim, H.-S. and Park, E.-M.** (2015). Visceral adipose tissue inflammation is associated with age-related brain changes and ischemic brain damage in aged mice. *Brain. Behav. Immun.* **50**, 221–231.
- Smith, C. J., Emsley, H. C. A., Gavin, C. M., Georgiou, R. F., Vail, A., Barberan, E. M., Zoppo, G. J., Hallenbeck, J. M., Rothwell, N. J., Hopkins, S. J., et al.** (2004). Peak plasma interleukin-6 and other peripheral markers of inflammation

in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. *BMC Neurol.* **4**, 1–8.

Smith, C. J., Emsley, H. C. A., Vail, A., Georgiou, R. F., Rothwell, N. J., Tyrrell, P. J. and Hopkins, S. J. (2006a). Variability of the systemic acute phase response after ischemic stroke. *J. Neurol. Sci.* **251**, 77–81.

Smith, C. a, Want, E. J., O'Maille, G., Abagyan, R. and Siuzdak, G. (2006b). XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. *Anal. Chem.* **78**, 779–87.

Springer, J., Schust, S., Peske, K., Tschirner, A., Rex, A., Engel, O., Scherbakov, N., Meisel, A., Von Haehling, S., Boschmann, M., et al. (2014). Catabolic signaling and muscle wasting after acute ischemic stroke in mice: Indication for a stroke-specific sarcopenia. *Stroke* **45**, 3675–3683.

Strazzullo, P., D'Elia, L., Cairella, G., Garbagnati, F., Cappuccio, F. P. and Scalfi, L. (2010). Excess body weight and incidence of stroke: meta-analysis of prospective studies with 2 million participants. *Stroke*. **41**, e418-26.

Sumner, L. W., Amberg, A., Barrett, D., Beale, M. H., Beger, R., Daykin, C. a., Fan, T. W.-M., Fiehn, O., Goodacre, R., Griffin, J. L., et al. (2007). Proposed minimum reporting standards for chemical analysis. *Metabolomics* **3**, 211–221.

Sun, N., Keep, R. F., Hua, Y. and Xi, G. (2016). Critical Role of the Sphingolipid Pathway in Stroke: a Review of Current Utility and Potential Therapeutic Targets. *Transl. Stroke Res.* **7**, 420–438.

Tang, W. and Wang, Z. (2009). Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk. *J Am Coll Cardiol* **53**, 2061–2067.

Terao, S., Yilmaz, G., Stokes, K. Y., Ishikawa, M., Kawase, T. and Granger, D. N. (2008). Inflammatory and injury responses to ischemic stroke in obese mice. *Stroke*. **39**, 943–50.

Trayhurn, P. and Wood, I. S. (2005). Signalling role of adipose tissue: adipokines and inflammation in obesity. *Biochem. Soc. Trans.* **33**, 1078–1081.

Vemmos, K., Ntaios, G., Spengos, K., Savvari, P., Vemmou, A., Pappa, T., Manios, E., Georgiopoulos, G. and Alevizaki, M. (2011). Association between

obesity and mortality after acute first-ever stroke: the obesity-stroke paradox. *Stroke*. **42**, 30–6.

- Wallace, M., Morris, C., O'Grada, C. M., Ryan, M., Dillon, E. T., Coleman, E., Gibney, E. R., Gibney, M. J., Roche, H. M. and Brennan, L.** (2014). Relationship between the lipidome, inflammatory markers and insulin resistance. *Mol. Biosyst.* **10**, 1586–95.
- Wang, Y.-Y., Lin, S.-Y., Chuang, Y.-H., Chen, C.-J., Tung, K.-C. and Sheu, W. H.-H.** (2011a). Adipose proinflammatory cytokine expression through sympathetic system is associated with hyperglycemia and insulin resistance in a rat ischemic stroke model. *Am. J. Physiol. Endocrinol. Metab.* **300**, E155-63.
- Wang, T. J., Larson, M. G., Vasan, R. S., Cheng, S., Rhee, E. P., McCabe, E., Lewis, G. D., Fox, C. S., Jacques, P. F., Fernandez, C., et al.** (2011b). Metabolite profiles and the risk of developing diabetes. *Nat. Med.* **17**, 448–53.
- Xia, J., Mandal, R., Sinelnikov, I. V, Broadhurst, D. and Wishart, D. S.** (2012). MetaboAnalyst 2.0--a comprehensive server for metabolomic data analysis. *Nucleic Acids Res.* **40**, W127-33.
- Zhang, Y. Y., Proenca, R., Maffei, M., Barone, M., Leopold, L. and Friedman, J. M.** (1994). Positional cloning of the mouse obese gene and its human homologue. *Nature* **372**, 425–432.
- Zhu, Y., Guo, Z., Zhang, L., Zhang, Y., Chen, Y., Nan, J., Zhao, B., Xiao, H., Wang, Z. and Wang, Y.** (2015). System-wide assembly of pathways and modules hierarchically reveal metabolic mechanism of cerebral ischemia. *Sci. Rep.* **5**, 1–15.
- Zimmermann, R., Strauss, J. G., Haemmerle, G., Schoiswohl, G., Birner-Gruenberger, R., Riederer, M., Lass, A., Neuberger, G., Eisenhaber, F., Hermetter, A., et al.** (2004). Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. *Science* **306**, 1383–6.

Tables

Table 1. Changes in plasma metabolites in naïve obese (*ob/ob*) compared to control (*ob/-*) mice.

Class	Metabolites	Fold (Ob/Cntrl)	95% CI Lower	95% CI Upper	P value
Acyl glycerides	DG(33:1)	1.82	1.52	2.22	0.0066
	TG(34:2)	0.47	0.35	0.62	0.0252
Amino acid metabolism	Arginine	0.14	0.02	0.26	0.0017
	Leucine; Isoleucine; Norleucine	1.43	1.28	1.59	0.0096
	Tryptophan	1.79	1.54	2.04	0.0270
	Phenylalanine	1.43	1.22	1.67	0.0355
Aromatic metabolite	Cresol	1.28	1.14	1.45	0.0426
Carbohydrate related	6-(alpha-D-Glucosaminy)-1D-myo-inositol	1.56	1.43	1.72	0.0019
	Deoxy-glucose; rhamnose; rhamnulose	0.53	0.40	0.69	0.0159
Ceramides and sphingolipids	GluCer(d18:1/18:0); GalCer(d18:1/18:0)	2.70	1.82	4.35	0.0287
	Sphinganine 1-phosphate	4.55	2.94	6.67	0.0484
Fatty acids related	Icosatrienoic acid (c20:3); eicosadienoic acid (c20:2)	0.21	0.14	0.29	0.0037
	Octadecanoic acid (C18:0)	1.69	1.41	2.04	0.0291
	Octadecatrenoic acid (C18:3)	0.71	0.60	0.85	0.0467
Glycerophospholipids	PC(O-15:0/O-1:0); PC(O-8:0/O-8:0); PC(O-16:0/0:0)	0.30	0.17	0.43	0.0027
	PC(O-16:0/3:0); PC(O-17:0/2:0); PC(O-18:0/1:0)	0.30	0.18	0.42	0.0035
	PE(42:9); PA(41:1)	2.27	1.79	2.94	0.0078
	PG(32:5)	1.92	1.64	2.27	0.0093
	PC(38:2)	2.33	1.79	3.13	0.0103
	PG(O-18:0/17:0); PG(O-20:0/15:0); PG(O-16:0/19:0)	2.78	2.38	3.23	0.0122
	PS(41:4); PS(39:1)	1.82	1.52	2.22	0.0123
	PC(O-16:0/17:0); PE(O-16:0/20:0)	2.78	2.04	3.85	0.0131
	PS(40:9); PE(40:10); PS(33:1)	0.32	0.18	0.50	0.0140
	PC(40:6); PC(38:3); PC(18:0/dm18:1)	1.92	1.59	2.33	0.0148
	PS(39:5); PS(36:2); PC(35:0)	2.33	1.67	3.45	0.0183
	PA(33:2)	2.63	1.85	4.17	0.0220
	PA(O-20:0/17:2); PA(P-18:0/19:1); PA(P-20:0/17:1)	1.59	1.35	1.85	0.0227

	PC(40:7); PC(38:4); PC(36:1)	2.04	1.45	3.03	0.0260
	PS(41:3); PS(39:0)	1.75	1.41	2.22	0.0268
	PS(41:2); PE(42:3); PC(38:3)	2.56	1.69	4.17	0.0270
	PC(38:4); PE(P-20:0/22:6); PS(O-18:0/19:1)	1.41	1.16	1.75	0.0426
	PS(43:6); PC(38:4)PC(36:1); PC(40:7)	1.61	1.30	2.08	0.0479
	PC(36:2)	2.56	1.72	4.00	0.0483
	PC(22:4/dm18:0); PS(39:3)	2.33	1.67	3.13	0.0493
Lysophospholipids	LysoPC(20:4); LysoPC(18:1)	1.54	1.37	1.75	0.0030
	LysoPC(18:2)	0.78	0.72	0.83	0.0037
	LysoPA(18:2)	0.35	0.24	0.46	0.0093
	LysoPC(dm18:1)	1.75	1.43	2.17	0.0103
	LysoPA(20:3); LPA(18:0); LPA(18:0)	0.81	0.75	0.88	0.0148
	LysoPS(12:0)	2.27	1.79	2.94	0.0168
	LysoPA(15:1)	0.59	0.48	0.72	0.0268
	LysoPC(20:1)	0.65	0.56	0.76	0.0269
	LysoPE(18:1)	0.49	0.29	0.70	0.0269
	LysoPC(18:1)	1.41	1.18	1.72	0.0331
	LysoPE(22:4)	1.59	1.35	1.85	0.0358
	LysoPC(18:0)	1.35	1.20	1.52	0.0358
	LysoPE(18:2); LysoPA(20:3)	0.43	0.26	0.63	0.0401
	LysoPC(22:1)	0.39	0.13	0.67	0.0432
Mixed classes	PA(34:0)	0.76	0.69	0.84	0.0172
	Palmitic amide; hexadecadienol	0.78	0.70	0.88	0.0217
	3-Dehydroxycarnitine; aminoheptanoic acid; methyllucine	1.79	1.41	2.27	0.0234
	Aconitate; Dehydroascorbic acid	3.70	2.22	7.69	0.0314
Nucleosides and nucleotides	UDP-N-acetylmuramate	1.67	1.39	2.04	0.0078
	Guanosine diphosphate adenosine	2.27	1.61	3.45	0.0166
	3-(ADP)-glycerate; lactic (2) diphospho-(5')guanosine	0.63	0.51	0.78	0.0460
	L-Alpha-Glycerophospho-D-Myo-Inositol-4,5-Bis-Phosphate; dITP	0.70	0.56	0.86	0.0469
Other classes	Pantothenic acid	2.50	1.89	3.33	0.0270
	Nicotinamide adenine dinucleotide phosphate	1.85	1.43	2.44	0.0285
	Lipoamide	1.89	1.47	2.44	0.0362
	3,5-Diiodo-4-hydroxyphenylpyruvate	1.54	1.27	1.85	0.0362

Oxidised fatty acids	Oxo-heptadecatrienoic acid (C17:3 oxo); hydroxy-heptadecatrienoic acid	1.89	1.67	2.13	0.0083
	2,3,4,5-tetranor-9S,11R,15S-trihydroxy-13E-prostenoic acid	0.38	0.21	0.56	0.0138
	Docosanol	1.64	1.37	2.04	0.0169
	Oxo-decadienoic acid (C10:2 oxo)	0.33	0.24	0.43	0.0220
	2,3-Dinor-8-iso prostaglandin F1alpha; hydroperoxy-epoxyoctadecenoic	2.08	1.56	2.70	0.0460
Peptides	L-gamma-glutamyl-L-isoleucine; L-gamma-glutamyl-L-leucine	1.89	1.56	2.27	0.0167
	Glutamyl-phenylalanine	1.89	1.54	2.27	0.0285
Sugar alcohol	Erythronic acid; Threonic acid	0.50	0.41	0.60	0.0093

Fold change is obese (Ob) divided by control (Cntrl). Metabolites are listed from most to least significant in each class. In the fold change column, metabolites increased in *ob/ob* relative to *ob/-* mice are in red, and metabolites decreased in *ob/ob* relative to *ob/-* mice are in blue. *P* values are FDR adjusted. The species listed are the potential identifies of each metabolite. *n* = 5-6 animals per group. ADP – adenosine diphosphate, Cer – ceramide, DG – Diglyceride, dITP – deoxyinosine triphosphate, GalCer – galactosylceramide, GluCer – glucosylceramide, MG – Monoglyceride, PA – phosphatidic acid, PC – phosphatidylcholine, PE – phosphatidylethanolamine, PG – phosphatidylglycerol, PS – phosphatidylserine, SM – sphingomyelin, TG – triglyceride, UDP – uridine diphosphate.

Table 2. Changes in plasma metabolites in obese (*ob/ob*) compared to control (*ob/-*) mice 24 h post-stroke.

Class	Metabolites	Fold (Ob/Cntrl)	95% CI Lower	95% CI Upper	P value
Acyl carnitines	Propanoylcarnitine	2.38	1.64	3.23	0.0371
Acyl glycerides	DG(34:4)	1.49	1.23	1.85	0.0181
	MG(22:2)	2.44	1.85	3.13	0.0396
	DG(40:9)	1.45	1.18	1.79	0.0399
	DG(34:3); DG(32:0)	0.40	0.17	0.71	0.0482
Amino acid metabolism	Methionine S-oxide	0.59	0.45	0.75	0.0135
	N-Succinyl-L-glutamate	2.33	1.67	3.23	0.0193
	Methionine	0.64	0.47	0.81	0.0238
	Tyrosine	0.58	0.46	0.74	0.0292
	Taurine	1.96	1.47	2.50	0.0310
	N-Acetyl-citrulline	1.61	1.27	2.04	0.0331
	S-Glutaryldihydroipoamide	2.22	1.52	2.94	0.0468
Aromatic metabolite	Indole-3-acetate; 3-indoleglycolaldehyde; 5-hydroxyindoleacetaldehyde	3.45	2.33	4.76	0.0312
Carbohydrates related	Sorbitol; galactitol; mannitol	0.60	0.51	0.71	0.0167
	N-Acetyl-O-acetylneuraminate	0.56	0.43	0.71	0.0180
	sn-glycero-3-Phospho-1-inositol; 2-(alpha-D-Galactosyl)-sn-glycerol 3-phosphate	2.27	1.64	3.03	0.0263
Ceramides and sphingolipids	SM(d18:1/18:0); SM(d18:0/18:1)	3.33	2.33	5.56	0.0004
	SM(d18:1/20:0)	0.35	0.22	0.48	0.0005
	N-(2-hydroxydodecanoyl)-4,8-sphingadienine	1.92	1.43	2.63	0.0161
	SM(d18:1/18:1)	2.08	1.43	3.33	0.0221
	Cer(d18:2/15:0)	1.89	1.32	3.13	0.0334
	SM(d18:1/14:0)	1.96	1.32	3.45	0.0337
Fatty acid related	Octadecadienoic acid (C18:2)	0.63	0.56	0.69	0.0001
	Decyl hexacosanoate; dodecyl tetracosanoate; eicosanyl hexadecanoate	1.56	1.28	1.89	0.0174
	Hexadecadienoic acid (C16:2)	1.85	1.33	2.56	0.0393
	Methyl-tetradecanedioic acid; pentadecanedioic acid (C15:0)	0.69	0.53	0.87	0.0445
	Eicosanyl oleate	1.89	1.25	3.13	0.0476
	Icosatetraenoic acid; eicosatetraenoic acid (C20:4)	1.43	1.19	1.75	0.0478

	Methyl-eicosadienoic acid; heneicosadienoic acid (C21:2)	1.64	1.22	2.17	0.0480
	Dodecanamide (C12:1)	0.71	0.58	0.87	0.0493
Fatty acid-amino acid esters	N-hexadecanoylglycine	1.85	1.32	2.78	0.0317
Glycerophospholipids	PA(O-18:0/22:2); PA(O-20:0/20:2); PA(P-18:0/22:1)	0.75	0.71	0.79	0.0001
	PE(34:2)	0.26	0.14	0.40	0.0016
	PS(P-20:0/22:4); PS(O-18:0/22:2); PS(O-20:0/20:2)	1.79	1.56	2.04	0.0032
	PC(20:5/dm18:1); PC(22:6/dm16:0); PS(37:5)	2.17	1.85	2.50	0.0085
	PC(33:2); PE(36:1); PA(38:3)	0.69	0.64	0.76	0.0180
	PC(34:2); PE(37:2)	2.22	1.64	3.33	0.0186
	PS(39:1); PC(22:5/dm18:1); PC(22:6/dm18:0)	0.82	0.74	0.90	0.0188
	DG(38:6)	0.50	0.28	0.72	0.0189
	PC(36:4); PC(34:1); PA(41:5)	1.82	1.54	2.70	0.0238
	PC(38:7); PC(36:4); PC(34:1)	2.08	1.43	2.27	0.0238
	PG(O-20:0/18:0); PG(O-18:0/20:0); PG(O-16:0/22:0)	0.40	0.15	0.66	0.0259
	PE(14:0/dm16:0)	2.27	1.59	3.23	0.0264
	PC(34:1); PA(39:2)	1.72	1.39	2.13	0.0285
	PA(O-16:0/18:4); PA(P-16:0/18:3)	2.08	1.45	3.13	0.0297
	PS(36:2); PE(38:6); PC(33:3)	0.50	0.35	0.68	0.0304
	PC(18:0/dm18:0); PC(20:0/dm16:0); PC(O-16:0/20:1)	1.56	1.27	1.89	0.0309
	PS(39:5); PS(37:2); PE(38:0)	1.89	1.32	2.78	0.0313
	PI(36:3)	1.79	1.37	2.22	0.0382
	PS(O-20:0/19:1); PS(P-18:0/21:0); PS(P-20:0/19:0)	0.56	0.50	0.79	0.0396
	PA(24:0); PC(O-18:1/0:0); PC(P-18:0/0:0)	0.64	0.42	0.72	0.0396
	PG(O-18:0/19:1); PG(O-20:0/17:1); PG(P-16:0/21:0)	2.50	1.69	3.33	0.0408
	PA(O-20:0/22:4)	1.43	1.18	1.72	0.0413
	PA(P-20:0/22:4); PG(O-20:0/14:1); PG(O-18:0/16:1)	2.27	1.49	3.45	0.0421
Lysophospholipids	LysoPE(20:2)	0.67	0.62	0.72	0.0001
	LysoPA(19:3)	2.22	1.69	3.13	0.0090
	LysoPC(dm18:1)	1.92	1.56	2.33	0.0100
	LysoPC(20:4); LysoPC(18:1)	1.59	1.35	1.85	0.0119
	LysoPI(20:4)	2.50	1.85	3.45	0.0265
	LysoPC(20:5)	1.59	1.23	2.13	0.0344
	LysoPE(20:4)	1.56	1.23	1.96	0.0351

	LysoPC(22:5)	0.68	0.55	0.81	0.0424
Mixed classes	Aminoadipate 6-semialdehyde; N-butyrylglycine	0.65	0.52	0.80	0.0396
Other classes	Pantothenic acid	4.00	3.13	5.00	0.0097
	Ethanolamine	0.63	0.54	0.75	0.0185
Oxidised fatty acids	Hydroxy-hexadecandioic acid (C16:0 double hydroxy)	0.76	0.71	0.82	0.0032
	12-keto-tetrahydro-Leukotriene B4; 11-deoxy-PGE1; 11-deoxy-PGF2a	0.45	0.29	0.65	0.0140
	Oxo-heneicosanoic acid (C21:0 oxo)	1.52	1.30	1.72	0.0159
	Hydroxy-Decenediynoic acid; oxo-decatetraenoic acid (c10 oxo)	0.56	0.42	0.72	0.0291
	N-Acetylleukotriene E4; N-acetyl-LTE4	0.58	0.45	0.72	0.0396
	Oxo-hydroxy-hexadecadienoate (C16:2 oxy)	1.82	1.52	2.13	0.0400
	Prostaglandin E3; prostaglandin D3; 8-iso-15-keto-PGE2	0.83	0.74	0.93	0.0450
	Trihydroxy-octadecenoic acid (C18: oxo3)	1.43	1.19	1.67	0.0468
	Oxo-octadecanoic acid (C18:0 oxy); hydroxyoctadecenoic acid (C18:1 oxy)	1.45	1.15	1.89	0.0472
	Hydroxystearate (C18:0 oxy)	1.49	1.20	1.89	0.0481
	Oxo-tetradecanoic acid (C14 oxo); hydroxy-tetradecenoic acid	1.96	1.35	2.70	0.0500
Peptides	Aspartyl-glutamic acid; N-acetyl-seryl-aspartate	1.61	1.35	1.89	0.0457
Short chain organic acids	Itaconate; Mesaconate; Acetylpyruvate	1.61	1.35	1.89	0.0454
Steroid metabolism	Corticosterone; deoxycortisol	2.44	1.72	3.33	0.0246
	Androsterone sulfate; dihydrotestosterone sulfate	2.38	1.61	3.85	0.0396
Sulphated metabolite	Indoxyl sulfate	3.57	2.22	8.33	0.0034
	3-Sulfodeoxycholic acid	1.56	1.23	1.92	0.0324
	Tetradecyl sulfate	0.83	0.74	0.93	0.0469

Fold change is obese (Ob) divided by control (Cntrl). Metabolites are listed from most to least significant in each class. In the fold change column, metabolites increased in *ob/ob* relative to *ob/-* mice are in red, and metabolites decreased in *ob/ob* relative to *ob/-* mice are in blue. *P* values are FDR adjusted. The species listed are the potential identifies of each metabolite. Any metabolites that were significantly affected by obesity in the naïve comparison (Table 1) were excluded from this list. *n* = 5-8 animals per group. ADP – adenosine diphosphate, Cer – ceramide, DG – Diglyceride, dITP – deoxyinosine triphosphate, GalCer – galactosylceramide, GluCer – glucosylceramide, MG – Monoglyceride, PA – phosphatidic acid, PC – phosphatidylcholine, PE – phosphatidylethanolamine, PG – phosphatidylglycerol, PS – phosphatidylserine, SM – sphingomyelin, TG – triglyceride, UDP – uridine diphosphate.

Figures




Fig. 1. Stroke had differential effects on fatty acid metabolism in obese (*ob/ob*) and control (*ob/-*) mice. (A) No significant correlation between body weight loss from the day of surgery to 24 h post-stroke and ischaemic infarct volume was found. (B) Blood glucose was measured in tail vein blood pre-surgery and at 24 h post-stroke. In naïve animals and at 24 h post-stroke, free fatty acid and glycerol concentrations were measured in plasma from cardiac blood (C) and epididymal fat homogenates (D). Triglyceride and glycerol measurements were made in liver homogenates (E). Data are mean \pm s.e.m., $n = 10$ for naïve, $n = 14$ for stroke group, $n = 6$ for lesion volume analysis, $*P < 0.05$ versus control *ob/-* for same treatment, $\#P < 0.05$ versus pre-surgery or naïve for same genotype using (A) Student's *t*-test or (B-E) two-way ANOVA with Šídák correction for multiple comparisons.




Fig. 2. Obesity differentially affected the expression of the lipolytic enzymes HSL and ATGL in epididymal adipose tissue after stroke. Expression of hormone sensitive lipase (HSL) (A), serine-563 phosphorylated HSL (B) and adipose triglyceride lipase (ATGL) (C) was quantified by western blot in epididymal adipose tissue homogenates in naïve control *ob/-* and obese *ob/ob* animals, or at 24 h post-stroke. Data are mean \pm s.e.m., $n = 10$ for naïve and $n = 14$ for stroke groups, $*P < 0.05$ versus control *ob/-* for same treatment, $\#P < 0.05$ versus naïve for same genotype using two-way ANOVA with Šídák correction for multiple comparisons. Densitometry values were normalised to β -actin as a loading control.




Fig. 3. Obesity altered the expression of inflammatory mediators and adipokines in the plasma and metabolically active organs after stroke.

Measurements were made in plasma from tail vein blood immediately prior to surgery (Pre) and at 24 h post-stroke (A). Measurements were also made in epididymal fat pad (B) and liver (C) homogenates taken from naïve animals or at 24 h post-stroke, and normalised to milligram of total protein as measured by BCA assay. Cytokine (IL-6, TNF α , CCL2, CXCL1, G-CSF) concentrations were measured by CBA. ICAM-1, adiponectin and resistin concentrations were measured by ELISA. Data are mean \pm s.e.m., $n = 10$ for naïve and $n = 14$ for stroke groups, $*P < 0.05$ versus control *ob*^{-/-} for same treatment, $\#P < 0.05$ versus pre-surgery or naïve for same genotype using two-way ANOVA with Šídák correction for multiple comparisons. N.D. = not detected.




Fig. 4. Principal component (PC) analysis plots for metabolomics data generated using UHPLC-MS in negative (A) and positive (B) ion modes. Analysis was performed on plasma 24 h after stroke or in naïve control (*ob/-*) and obese (*ob/ob*) mice. $n = 5-8$ animals per group. QC, quality control. Data on class of metabolites presented in Fig. 5.




Fig. 5. Obesity affected the metabolic response to stroke. Classification of plasma metabolites that were significantly different between control (*ob/-*) and obese (*ob/ob*) mice in naïve mice (A) and at 24 h post-stroke (B). Any metabolites that were significantly affected by obesity in the naïve comparison were excluded from the list of metabolites affected by obesity in the 24-h post-stroke comparison. *n* = 5-8 animals per group.




Fig. 6. A summary of the inflammatory and metabolic changes observed in obese *ob/ob* mice acutely (24 h) after stroke, and how we hypothesise they may be related. Black text indicates no significant effect, red text indicates observations of significant increases, blue text indicates significant decreases, and purple text indicates both significant increases and decreases within this category. We hypothesise that acute brain damage caused by hypoxia signals to the liver and adipose tissue either by humoral or neuronal routes. This leads to alterations in expression and release of inflammatory cytokines, which may impact on the metabolic functions of the liver and adipose tissue. For example, pro-inflammatory cytokines can promote lipolysis, and promote transport of FFA into the blood. The liver and adipose tissue may also release cytokines in the circulation. Membrane lipids found in the blood may be partially derived from damaged membranes within the CNS.